ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Terns buys Lilly liver disease compounds

by Lisa M. Jarvis
April 9, 2018 | APPEARED IN VOLUME 96, ISSUE 15

Eli Lilly & Co. has sold Terns Pharmaceuticals the rights to three small-molecule drug candidates for nonalcoholic steatohepatitis (NASH), a liver disease. The biotech firm is gaining a farnesoid X receptor agonist, a semicarbazide-sensitive amine oxidase inhibitor, and a preclinical molecule against an undisclosed drug. Terns will first develop the compounds in China. No drugs are approved to treat NASH, which is estimated to afflict up to 5% of the world’s population.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment